New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
16:07 EDTINSYTop prescriber of Insys drug probed for fraud, MLive says
Dr. Gavin Awerbuch, a neurologist that was paid $6.9M from 2009, through Feb. 6, 2014, for his prescriptions of Insys Therapeutics' cancer pain drug Subsys, was arraigned in federal court in Detroit on May 6 on charges of health care fraud, reported MLive yesterday. "Awerbuch is responsible for approximately 20.3% of the Subsys prescribed to Medicare beneficiaries nationwide during this time," the affidavit stated, according to the report. Shares of Insys were down more than 16% today. Reference Link
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
17:08 EDTINSYInsys Therapeutics receives purported service of notice of three IPR petitions
On August 26, Insys Therapeutics received purported service of notice of three inter partes review petitions filed by a hedge fund with the U.S. Patent and Trademark Office, challenging three of the four Orange Book-listed patents covering Subsys. The company intends to oppose the request to institute the IPR and, if any of the three petitions are granted, the company intends to defend the validity of each patent challenged in each IPR.
August 18, 2015
08:16 EDTINSYInsys Therapeutics files citizen petition with DEA to reschedule synthetic CBD
Insys Therapeutics announced it has filed a Citizen Petition with the DEA to request the agency reschedule its synthetic pharmaceutical cannabidiol, or CBD, from Schedule I to Schedule IV. The company believes that the current classification of synthetic CBD as a Schedule I compound is a significant barrier to the progress of research studies that explore the value of this compound in the treatment of several serious medical conditions.
August 17, 2015
12:24 EDTINSYInsys dronabinol oral solution NDA accepted for filing by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use